AstraZeneca shareholders question Pfizer deal

Name: AstraZeneca shareholders question Pfizer deal
Uploaded: 2014-05-19T16:05:37.000Z
Duration: 1 min 11 s
Description: Aberdeen Asset Management's Anne Richards tells BBC News about the shareholders' reaction to the latest Pfizer bid rejection at AstraZeneca.

This video can not be played

To play this video you need to enable JavaScript in your browser.

UK drugs company AstraZeneca has rejected an improved "final" takeover offer from US drugs giant Pfizer.

Pfizer had made a new offer of £55 per share, valuing AstraZeneca at about £69bn.

Aberdeen Asset Management's Anne Richards told BBC News about some of the shareholders' reaction to the latest bid rejection.

Business

19 May 2014